Figure 3.

CSF IGFBP2 is associated with longitudinal changes in delayed memory and visuospatial abilities over 5–8 years in PREVENT-AD. CSF IGFBP2 levels were measured using the Olink Proximity Extension Assay (n = 109). Cognitive performance trajectory slopes were computed for each cognitive domain of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS; delayed memory, visuospatial abilities, language, immediate memory and attention) in a subset of PREVENT-AD participants that were followed for 5–8 years (n = 89). Significant linear regressions are represented with a confidence region of the fitted line. R², β- and P-values are located in the top right corner. Analyses were adjusted for age, sex, APOE ɛ4 carrier status and years of education. IGFBP2 = insulin-like growth factor binding protein-2; NPX = Normalized Protein eXpression; PREVENT-AD = PRe-symptomatic EValuation of Experimental or Novel Treatments for Alzheimer's Disease.